Cure8 research brief
The paper describes a preclinical demonstration that a plant-derived compound reduced inflammation and changed gut microbiota and metabolite profiles in a mouse colitis model, suggesting a possible route for future microbiome-targeted IBD treatments.
Researchers, clinicians interested in microbiome or dietary interventions for IBD, and informed patients following experimental therapies
The study used a DSS mouse model (an experimental colitis model) to test Yakuchinone B (YB). Mice receiving YB had smaller weight loss, lower disease-activity scores, less colon shortening, and improved histology compared with untreated DSS mice. YB-treated mice showed lower colonic and serum inflammatory cytokines (TNF-α, IL-1β, IL-6).
Microbiome profiling and metabolomics in the study found shifts in bacterial taxa and increases in short-chain fatty acids (acetate, propionate, butyrate) alongside changes in metabolic pathways. The findings are from an animal experiment and report biological effects and mechanisms (microbiota and metabolites) rather than clinical benefits in people.
This is exploratory preclinical research that can motivate further study but does not provide evidence to support use of YB in patients.
Results come from a DSS-induced mouse model and laboratory analyses (microbiome profiling, metabolomics). Findings are exploratory and not evidence of benefit or safety in people.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Natural Science Foundation of China, award 32360579; award 32360579
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study shows a probiotic strain reduced inflammation and improved gut barrier and microbiome/metabolite profiles in a mouse colitis model, indicating a possible new avenue for UC therapies worth further research.
A natural compound (C3G) reduced inflammation and changed gut bacteria and metabolites in an experimental colitis model, pointing to possible new mechanisms or leads for IBD therapies.
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
